Immunoliposomes bearing lymphocyte activation gene 3 fusion protein and P5 peptide: A novel vaccine for breast cancer,Biotechnology Progress

当前位置： X-MOL 学术 › Biotechnol. Prog. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Immunoliposomes bearing lymphocyte activation gene 3 fusion protein and P5 peptide: A novel vaccine for breast cancer
Biotechnology Progress ( IF 2.9 ) Pub Date : 2020-10-29 , DOI: 10.1002/btpr.3095
Saeed Mohammadian Haftcheshmeh _{1,

2,

3} , Parvin Zamani _{2,

4} , Mohammad Mashreghi _{2,

5} , Amin Reza Nikpoor ₆ , Jalil Tavakkol-Afshari ₇ , Mahmoud Reza Jaafari _{2,

5,

8}

Affiliation

LAG3‐Ig as an immune adjuvant has elicited potent anti‐tumor immune responses in several preclinical and clinical studies, but the full potential immunostimulatory of LAG3‐Ig has yet to be achieved. We hypothesized that by anchoring LAG3‐Ig to the surface of liposomes, the adjuvant activity of LAG3‐Ig could be improved. We also investigated the immunotherapy by co‐delivery of liposome‐coupled LAG3‐Ig and P5 tumor antigen in mice model of TUBO breast cancer. We prepared and characterized novel PEGylated liposomes bearing surface conjugated LAG3‐Ig and P5. Consistent with our hypothesis, liposomes‐conjugated LAG3‐Ig via multivalent binding to MHC class II molecules exerted immunostimulatory of LAG3‐Ig and markedly induced maturation of dendritic cells more efficiently than free LAG3‐Ig. LAG3‐Ig‐P5‐immunoliposomes effectively elicited protective anti‐tumor responses more than locally injected soluble LAG3‐Ig + P5. The higher percentage of CD4⁺ and CD8⁺ T cells in the spleen and more rapid and pronounced infiltration of these effector cells into the site of the tumor were seen following immunoliposome therapy. Finally, anti‐tumor immunity induced by LAG3‐Ig‐P5‐immunoliposomes translated into the more tumor regression and prolonged survival of treated mice, compared to soluble immunotherapy. Taken together, our findings suggest that LAG3‐Ig‐P5‐immunoliposomes can be considered as a valuable candidate for developing a liposome‐based therapeutic cancer vaccine in treating HER2/ neu⁺ breast cancer patients.

更新日期：2020-10-29

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南

全部期刊列表>>